Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 18, 2022
- Revision received November 8, 2022
- Published online April 28, 2023.
Article Versions
- previous version (December 29, 2022 - 08:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Nader Hirmas1,
- Rainer Hamacher2,
- Miriam Sraieb1,
- Marc Ingenwerth3,
- Lukas Kessler1,
- Kim M. Pabst1,
- Francesco Barbato1,
- Katharina Lueckerath1,
- Stefan Kasper2,
- Michael Nader1,
- Hans-Ulrich Schildhaus3,4,
- Claudia Kesch5,
- Bastian von Tresckow6,
- Christine Hanoun6,
- Hubertus Hautzel1,
- Clemens Aigner7,
- Martin Glas8,
- Martin Stuschke9,
- Sherko Kümmel10,
- Philipp Harter11,
- Celine Lugnier12,
- Waldemar Uhl13,
- Marco Niedergethmann14,
- Boris Hadaschik5,
- Viktor Grünwald5,
- Jens T. Siveke15,16,
- Ken Herrmann1 and
- Wolfgang P. Fendler1
- 1Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany;
- 2Department of Medical Oncology, West German Cancer Center, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 3Institute of Pathology, University Hospital Essen, Essen, Germany;
- 4Targos Molecular Pathology Inc., Kassel, Germany;
- 5Department of Urology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 6Department of Hematology and Stem Cell Transplantation, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 7Department of Thoracic Surgery and Thoracic Endoscopy, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 8Division of Clinical Neurooncology, Department of Neurology, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 9Department of Radiation Therapy, University of Duisburg–Essen, and DKTK–University Hospital Essen, Essen, Germany;
- 10Breast Unit, Kliniken Essen–Mitte, Essen, Germany, and Department of Gynecology with Breast Center, Charité–Universitätsmedizin Berlin, Berlin, Germany;
- 11Department of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen–Mitte, Essen, Germany;
- 12Department of Hematology and Oncology with Palliative Care, Ruhr University Bochum, Bochum, Germany;
- 13Department of General and Visceral Surgery, Ruhr University Bochum, Bochum, Germany;
- 14Clinic for General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany;
- 15Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany; and
- 16Division of Solid Tumor Translational Oncology, DKTK (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany
- For correspondence or reprints, contact Wolfgang P. Fendler (wolfgang.fendler{at}uk-essen.de).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
- 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
- Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives
- Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial